| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/1076029616652727 |
| P698 | PubMed publication ID | 27268941 |
| P50 | author | Vijaya Raj Bhatt | Q84159877 |
| P2093 | author name string | Krishna Gundabolu | |
| Prajwal Dhakal | |||
| P2860 | cites work | Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q24633053 |
| Novel antidotes for target specific oral anticoagulants | Q26784125 | ||
| Thrombosis in paroxysmal nocturnal hemoglobinuria | Q26853483 | ||
| Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism | Q26864305 | ||
| A specific antidote for dabigatran: functional and structural characterization | Q27684149 | ||
| Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women's Health Study | Q28221298 | ||
| Idarucizumab for Dabigatran Reversal | Q28263802 | ||
| Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial | Q28265484 | ||
| Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity | Q28278166 | ||
| Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients | Q33341941 | ||
| Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q33399576 | ||
| Syndromes of thrombotic microangiopathy | Q33417044 | ||
| A 14-year study of heparin-induced thrombocytopenia | Q33497877 | ||
| Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). | Q34012421 | ||
| Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force | Q34044753 | ||
| Clinical guidelines for testing for heritable thrombophilia | Q34096556 | ||
| Thrombotic storm revisited: preliminary diagnostic criteria suggested by the thrombotic storm study group | Q34173133 | ||
| Aspirin for preventing the recurrence of venous thromboembolism | Q34276812 | ||
| Management of venous thromboembolic diseases and the role of thrombophilia testing: summary of NICE guidance | Q34284649 | ||
| Low-dose aspirin for preventing recurrent venous thromboembolism | Q34309660 | ||
| ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing | Q34320780 | ||
| 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism | Q34436061 | ||
| Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. | Q34501375 | ||
| Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report | Q34513594 | ||
| Venous thromboembolism in the outpatient setting | Q34581299 | ||
| Evidence-based approach to thrombophilia testing | Q34663749 | ||
| Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology | Q34946830 | ||
| Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy | Q36841584 | ||
| Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism? | Q37259068 | ||
| Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies | Q37363885 | ||
| Prothrombin complex concentrates used alone in urgent reversal of warfarin anticoagulation | Q37733748 | ||
| Catastrophic antiphospholipid syndrome: updated diagnostic algorithms | Q37778890 | ||
| Clinical practice. Deep-vein thrombosis of the upper extremities | Q37848837 | ||
| Management of antithrombotic therapy in patients undergoing invasive procedures | Q38110302 | ||
| Clinical significance and management of subsegmental pulmonary embolism | Q38378484 | ||
| Direct Oral Anticoagulants and Their Use in Treatment and Secondary Prevention of Acute Symptomatic Venous Thromboembolism | Q38578564 | ||
| Screening for Occult Cancer in Unprovoked Venous Thromboembolism | Q41653423 | ||
| How I treat incidental pulmonary embolism | Q41658217 | ||
| Epidemiology of venous thromboembolism | Q41667853 | ||
| Fondaparinux for the Treatment of Superficial-Vein Thrombosis in the Legs | Q42879815 | ||
| Clinical relevance of symptomatic superficial-vein thrombosis extension: lessons from the CALISTO study | Q43715410 | ||
| Oral apixaban for the treatment of acute venous thromboembolism | Q43741993 | ||
| The risk of venous thrombosis in individuals with a history of superficial vein thrombosis and acquired venous thrombotic risk factors | Q43975168 | ||
| Risk profile and clinical outcome of symptomatic subsegmental acute pulmonary embolism. | Q45033941 | ||
| The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism | Q45298422 | ||
| Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry | Q45733241 | ||
| Protamine reversal of low molecular weight heparin: clinically effective? | Q45873685 | ||
| Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the Cancer-DACUS Study. | Q47433540 | ||
| Body height and risk of venous thromboembolism: The Tromsø Study | Q47434717 | ||
| Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). | Q47923995 | ||
| Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial | Q47939603 | ||
| Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. | Q47958105 | ||
| D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. | Q50595629 | ||
| A prospective cohort study on the absolute incidence of venous thromboembolism and arterial cardiovascular disease in asymptomatic carriers of the prothrombin 20210A mutation. | Q50783894 | ||
| Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. | Q51127208 | ||
| Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrat | Q53539960 | ||
| D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study | Q56973674 | ||
| The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis | Q57573610 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 511-517 | |
| P577 | publication date | 2016-06-05 | |
| P1433 | published in | Clinical and Applied Thrombosis-Hemostasis | Q5133805 |
| P1476 | title | An Algorithmic Approach to Management of Venous Thromboembolism | |
| P478 | volume | 23 |
| Q89687743 | Cancer Screening in Patients with Unprovoked Thromboembolism: How to do it and Who Benefits? | cites work | P2860 |
Search more.